ÅLESUND, NORWAY – May 12, 2021 – Hofseth BioCare ASA (HBC), a Norwegian biotech company developing high quality ingredients and finished products, announced today that it has entered into a global innovation partnership with Catalent, the world’s leading advanced delivery company is technologies, development and manufacturing solutions for pharmaceuticals, biologics, cell and gene therapies, and consumer health products to develop a sustained-release formulation of OmeGo® fish oil from HBC.
As part of the partnership, Catalent will use its proprietary OptiGel® DR technology to encapsulate OmeGo®, HBC’s unique fish oil made from sustainable, traceable and fresh Norwegian Atlantic salmon. OptiGel DR technology enables an enteric release profile for capsules with no additional outer coating, using a one-step manufacturing process that avoids the heat and drying of the coating process that could otherwise break down the fish oil.
HBC is currently conducting studies to investigate the potential role of OmeGo® fish oil in preventing disease progression and reducing inflammation, including in patients with inflammation caused by COVID-19. The results are expected in the coming months and offer deep insights into the potential of OmeGo® fish oil to help the body release inflammation caused by a viral infection.
“Our research into the health benefits of our unique oil has come a long way in the past 18 months. We look forward to working with Catalent and hope to further expand the partnership to leverage the innovative oral technologies and ensure the effectiveness of the delivery system, ”commented Dr. Bomi Framroze, HBC Scientific Director. “OptiGel DR will enhance the OmeGo franchise, bring in advanced delivery technologies and raise its profile among the world’s leading healthcare companies.”
“This partnership is an exciting opportunity to combine the properties of a high quality ingredient with our new OptiGel DR capsule technology to create a product that offers consumers optimal benefits and experiences,” commented Dr. Aris Gennadios, President of Softgel and Oral Technologies, Catalan. “Our rich history and innovation in softgel technology has enabled us to develop a dosage form that delivers ingredients and formulations with an enteric release profile in robust capsules and with product performance that meets consumer expectations.”
Introduced by Catalent in 2020, OptiGel DR capsule technology gives innovators the ability to formulate products in a patient-preferred softgel dosage form with a sustained-release profile that offers many benefits, including protection from active ingredients trapped by stomach acid These active ingredients can be broken down and released directly in the intestine, where they are absorbed, possibly improving bioavailability. The technology also preserves the clarity of the capsule, which is important for HBC to showcase the distinctive color of OmeGo® fish oil, and maintains the distinctive swallowability that consumers associate and prefer with softgel dosage forms.
You can find more information about OptiGel DR at https://consumerhealth.catalent.com/nutritional-supplements/dose-forms/optigel-dr-softgel-technology
For more information please contact:
James Berger, Commercial Director of Hofseth BioCare ASA
Phone: +41 79 950 10 34
Catalent is the world’s leading provider of advanced delivery technology, development and manufacturing solutions for pharmaceuticals, biologics, cell and gene therapies, and consumer health products. Catalent has been in the industry for over 85 years and has a proven track record of bringing more customer products to market faster, improving product performance, and ensuring reliable global clinical and commercial product supplies. Catalent employs approximately 15,000 people, including approximately 2,400 scientists and technicians, in more than 45 facilities and had annual sales of over $ 3 billion in fiscal 2020. Catalent is headquartered in Somerset, New Jersey. More information is available at www.catalent.com
More products. Better treatments. Reliably delivered. ™
About Hofseth BioCare ASA
HBC is a Norwegian biotech company developing high quality ingredients and finished products currently targeting the consumer health market. Research is currently being carried out to identify the individual elements in the products that modulate inflammation and the immune response. This is done through pre-clinical studies in several clinics and university research laboratories in several countries. Leading clinical and preclinical candidates for the protection of the gastrointestinal system (GI) against inflammation, including ulcerative colitis and necrotizing enterocolitis in orphan disease, as a medicinal food for the treatment of age-related sarcopenia and as the treatment of iron deficiency anemia, all using peptide fractions of salmon protein hydrolyzate. Preclinical studies with the oil for the relief of pneumonia in eosinophilic asthma and COPD (“smoker’s lung”) as well as clinical work on COVID are currently being carried out.
The company is based on the fundamental values of sustainability and the optimal use of natural resources. Using innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon waste.
Hofseth BioCare is headquartered in Ålesund, Norway, with offices in Oslo, London, Zurich, Chicago, Mumbai, Palo Alto and Tokyo.
This information is subject to disclosure requirements under Section 5-12 of the Norwegian Securities Trading Act